Literature DB >> 9831423

Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features.

C Roozendaal1, A W Van Milligen de Wit, E B Haagsma, G Horst, C Schwarze, H H Peter, J H Kleibeuker, J W Tervaert, P C Limburg, C G Kallenberg.   

Abstract

PURPOSE: The clinical significance of antineutrophil cytoplasmic autoantibodies (ANCA) in primary sclerosing cholangitis has not been established. We investigated whether analysis of the antigenic specificities of ANCA is useful for delineating clinical subsets of the disease.
METHODS: Sixty-nine patients with primary sclerosing cholangitis were studied. The presence of ANCA was analyzed by indirect immunofluorescence. Antibodies directed against specific antigens--proteinase 3, myeloperoxidase, elastase, bactericidal/permeability-increasing protein, cathepsin G, and lactoferrin--were identified by enzyme-linked immunosorbent assay.
RESULTS: ANCA were detected by indirect immunofluorescence in 46 (67%) patients. In antigen-specific enzyme-linked immunosorbent assays, 37 (55%) of the 69 patients had antibodies to one or more antigens: 32 (46%) had antibodies to bactericidal/permeability-increasing protein, 16 (23%) had antibodies to cathepsin G, and 15 (22%) had antibodies to lactoferrin. Only 3 patients had antibodies to proteinase 3. Antibodies to myeloperoxidase or elastase were not detected. Twenty (29%) patients had antibodies to different antigens simultaneously. ANCA as detected by indirect immunofluorescence were not significantly associated with the presence of cirrhosis nor with the coexistence of inflammatory bowel disease. However, antibodies to bactericidal/permeability-increasing protein and cathepsin G were both associated with the presence of cirrhosis, and antibodies to lactoferrin were more frequently detected in patients with primary sclerosing cholangitis in conjunction with ulcerative colitis than in those without inflammatory bowel disease.
CONCLUSION: Defined specificities of ANCA in primary sclerosing cholangitis may be related to particular clinical features of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831423     DOI: 10.1016/s0002-9343(98)00294-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

Review 3.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 5.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

Review 6.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

Review 7.  Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases.

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 8.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 9.  Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; William F C Rigby
Journal:  J Transl Autoimmun       Date:  2021-05-28

10.  Differential Enhancement of Neutrophil Phagocytosis by Anti-Bactericidal/Permeability-Increasing Protein Antibodies.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; Rachel M Wierzbicki; Katherine J Sessions; William F C Rigby
Journal:  J Immunol       Date:  2021-07-16       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.